News
ASCO: Moderna, Merck melanoma vaccine set for phase 3
Moderna’s move into personalised cancer therapy continues to proceed at a rapid pace, with Merck & Co-partnered melanoma vaccine mRNA-4157 heading for a pivotal phase
